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Introduction {#os12716-sec-0005}
============

High‐grade bone sarcomas are aggressive tumors with a high potential of metastasis. Diagnosis and treatment of these neoplasms is challenging due to low incidences[1](#os12716-bib-0001){ref-type="ref"}, [2](#os12716-bib-0002){ref-type="ref"}, [3](#os12716-bib-0003){ref-type="ref"}, [4](#os12716-bib-0004){ref-type="ref"}, [5](#os12716-bib-0005){ref-type="ref"}.

Therefore, centralization of sarcoma care is important in order to realize a multidisciplinary approach by an experienced team[6](#os12716-bib-0006){ref-type="ref"}, [7](#os12716-bib-0007){ref-type="ref"}. Nowadays, the majority of patients with a primary bone sarcoma are diagnosed and treated in a bone sarcoma center. A few dozen bone sarcoma centers with expertise are scattered across Europe. However, as for differences in nationwide organization of care, the approach towards diagnosis and treatment differs between these hospitals. Further differences are seen in terms of patient adherence to bone sarcoma centers due to centralization of care. Based on a single study, treatment in a bone sarcoma center was associated with higher survival for high‐grade osteosarcoma patients[8](#os12716-bib-0008){ref-type="ref"}. However, this association was not seen for high‐grade chondrosarcoma and Ewing sarcoma patients. Furthermore, the optimal size for a bone sarcoma center in terms of patient adherence is not known at this moment. The European Musculoskeletal Oncology Society (EMSOS) aims to promote advances in science, disseminate knowledge, and promote mutual collaboration for bone sarcoma care between the different affiliated bone sarcoma centers.

This study aims to assess organization of care in several bone sarcoma centers in Europe affiliated with EMSOS for comparison and improvement of knowledge.

Methods {#os12716-sec-0006}
=======

The European Musculoskeletal Oncology Society (EMSOS) was founded in 1987. The particular purpose of EMSOS is to facilitate a network for different specialists and institutes in order to improve treatment of musculoskeletal tumors. This is realized by collaborative research projects and disseminating knowledge through an annual congress.

Data for this observational cross‐sectional study was obtained through healthcare professionals affiliated with EMSOS. The authors formulated 10 questions regarding organization of care and produced a digital questionnaire, which is displayed in the appendix. The questions were focused on guidance, multidisciplinary decision‐making, and data storage. The digital questionnaire was not validated. EMSOS members were approached as representatives from all over Europe. These representatives were asked to return this digital questionnaire. A flowchart of the study design was displayed in Fig. [1](#os12716-fig-0001){ref-type="fig"}. Observational research among healthcare professionals does not fall under the scope of the Dutch Act on Medical Scientific Research involving Human Beings (WMO).

![Flowchart of the study design.](OS-12-1030-g001){#os12716-fig-0001}

Analyses were performed using IBM SPSS Statistics for Windows (Version 23.0, United States) and Microsoft Excel 2013 (United States).

Results {#os12716-sec-0007}
=======

A digital questionnaire was sent to 54 representative members of EMSOS and we received a response from 25 representatives (46.3%) from 17 countries after one digital invitation and two digital reminders. These representatives were acknowledged as the EMSOS study group. The geographical dispersion across Europe of responding bone sarcoma centers was displayed in Fig. [2](#os12716-fig-0002){ref-type="fig"}. Questionnaire output data regarding bone sarcoma centers per country were displayed in Table [1](#os12716-tbl-0001){ref-type="table"}.

![Geographical dispersion across Europe of responding bone sarcoma centres. 1. Netherlands: University Medical Center Groningen, Leiden University Medical Center. 2. Belgium: Jules Bordet Institute Brussels. 3. Germany: Medical Center of the University of Munich, Stuttgart Cancer Center Olgahospital. 4. United Kingdom: University College Hospital London, Royal Orthopedic Hospital Birmingham. 5. France: Limoges Teaching Hospital, University Hospital Hotel‐Dieu Nantes, Hospital Cochin Paris. 6. Spain: Hospital Universitario de Bellvitge Barcelona, Hospital Universitario La Paz Madrid. 7. Italy: Centro Traumatologico Ortopedico Florence, Regina Elena National Cancer Institute Rome, Cancer Institute G. Pascal Foundation Naples. 8. Norway: Oslo University Hospital. 9. Sweden: Karolinska Hospital Stockholm. 10. Finland: Helsinki University Central Hospital. 11. Austria: Medical University of Graz. 12. Switzerland: Balgrist University Hospital Zürich. 13. Poland: Pomeranian Medical University of Szczecin. 14. Slovenia: Ljubljana University Medical Centre. 15. Serbia: Institute for Oncology and Radiology Belgrade. 16. Ukraine: National Cancer Institute Kiev. 17. Turkey: Acibadem Maslak Hospital Istanbul.](OS-12-1030-g002){#os12716-fig-0002}

###### 

Questionnaire output data regarding bone sarcoma centres per country

                   Number of bone sarcoma centres                     Million inhabitants in 2018[9](#os12716-bib-0009){ref-type="ref"}   Million inhabitants per bone sarcoma centre        Authorisation basis                                Bone tumor guideline   National bone tumor board   Number of cases discussed per week in local meeting   Referral to a bone sarcoma centre (%)              Treatment in a bone sarcoma centre (%)             Registry for oncological data
  ---------------- -------------------------------------------------- ------------------------------------------------------------------- -------------------------------------------------- -------------------------------------------------- ---------------------- --------------------------- ----------------------------------------------------- -------------------------------------------------- -------------------------------------------------- ---------------------------------------------
  Netherlands      4                                                  17.15                                                               4.28                                               Government                                         National               Yes                         25--30                                                90                                                 98                                                 National
  Belgium          5                                                  11.57                                                               2.31                                               Expertise                                          Local                  No                          12                                                    50                                                 90                                                 Local
  Germany          Not clear[\*](#os12716-note-0003){ref-type="fn"}   80.46                                                               Not clear[\*](#os12716-note-0003){ref-type="fn"}   Not clear[\*](#os12716-note-0003){ref-type="fn"}   National               No                          5--20                                                 Not clear[\*](#os12716-note-0003){ref-type="fn"}   Not clear[\*](#os12716-note-0003){ref-type="fn"}   Local[†](#os12716-note-0004){ref-type="fn"}
  United Kingdom   5                                                  65.11                                                               13.02                                              Government                                         National               Yes                         40                                                    90                                                 100                                                National
  France           12                                                 67.36                                                               5.61                                               Expertise                                          National               Yes                         15--40                                                90                                                 98                                                 National
  Spain            10                                                 49.33                                                               4.93                                               Expertise                                          National               No                          6--10                                                 70                                                 30                                                 Local
  Italy            10                                                 62.25                                                               6.22                                               Expertise                                          Local                  No                          10--15                                                90                                                 95                                                 Local
  Norway           2                                                  5.37                                                                2.69                                               Government                                         National               No                          10                                                    90                                                 100                                                Local
  Sweden           3                                                  10.04                                                               3.35                                               Government                                         National               Yes                         20                                                    95                                                 95                                                 National
  Finland          4                                                  5.54                                                                1.38                                               Government                                         Local                  Yes                         25                                                    90                                                 99                                                 Local
  Austria          4                                                  8.79                                                                2.19                                               Expertise                                          Local                  No                          15                                                    70                                                 90                                                 National
  Switzerland      5                                                  8.29                                                                1.66                                               Expertise                                          National               No                          12                                                    95                                                 N/A                                                Local
  Poland           5                                                  38.42                                                               7.68                                               Government                                         National               Yes                         4                                                     70                                                 80                                                 National
  Slovenia         1                                                  2.10                                                                2.10                                               Expertise                                          National               Yes                         12                                                    N/A                                                95                                                 National
  Serbia           1                                                  7.08                                                                7.08                                               Expertise                                          Local                  Yes                         10                                                    70                                                 80                                                 Local
  Ukraine          4                                                  43.95                                                               10.98                                              Government                                         National               No                          4                                                     50                                                 30                                                 National
  Turkey           5                                                  81.26                                                               16.25                                              Expertise                                          Local                  No                          20                                                    5                                                  20                                                 No registry

N/A, not available

In Germany bone sarcoma centres are not defined, therefore it is not clear where bone sarcoma patients are treated in this country

Cooperative German‐Austrian‐Swiss Osteosarcoma Study Group (COSS) and Cooperative German‐Austrian‐Swiss Ewing sarcoma Study Group (CESS) are multinational initiatives for registration of oncological data.

*Guidance* {#os12716-sec-0008}
----------

Authorization to perform oncological care in a bone sarcoma center was government issued in the Netherlands, the United Kingdom, Norway, Sweden, Finland, Poland, and Ukraine (41.2%). Authorization based on expertise without governmental influence was seen in Belgium, France, Spain, Italy, Austria, Switzerland, Slovenia, Serbia, and Turkey (52.9%). A lack of consensus towards authorization of bone sarcoma centers was seen in Germany, there are not a defined number of bone sarcoma centers in this country. In 64.7% of the countries, a national bone tumor guideline regarding diagnosis and treatment is used in oncological care. In Belgium, Italy, Finland, Austria, Serbia, and Turkey, local hospital guidelines are used for diagnosis and treatment (35.3%). Several (national) bone tumor guidelines, obtained through the questionnaire, are displayed in the appendix.

*Multidisciplinary Decision Making* {#os12716-sec-0009}
-----------------------------------

A national bone tumor board for extensive case evaluation including classification and advice for treatment is available in the Netherlands, the United Kingdom, France, Sweden, Finland, Poland, Slovenia, and Serbia (47.1%). All participating bone sarcoma centers have a mandatory local multidisciplinary meeting before the start of treatment; in the vast majority this meeting takes place once a week (84.0%). During this multidisciplinary meeting a median of 15 cases (range, 4--40 cases) are discussed. Regarding referral towards and treatment in a bone sarcoma center, most countries had percentages in the upper quartiles as shown in Table [1](#os12716-tbl-0001){ref-type="table"}. Lower referral percentages were seen in Belgium (50%), Ukraine (50%), and Turkey (5%). With regards to treatment in a bone sarcoma center, relatively low treatment percentages were seen in Spain (30%), Ukraine (30%), and Turkey (20%).

*Data storage* {#os12716-sec-0010}
--------------

A local registry for oncological data is used in Belgium, Germany, Spain, Italy, Norway, Finland, Switzerland, and Serbia (47.1%). A national registry is used in the Netherlands, the United Kingdom, France, Sweden, Austria, Poland, Slovenia, and Ukraine (47.1%). Bone tumors are not registered in Turkey (5.8%).

Discussion {#os12716-sec-0011}
==========

Dedicated health care professionals all over Europe perform bone sarcoma care. This is the first study to provide cross‐sectional data regarding organization of bone sarcoma care in Europe. A wide range of centralization across Europe was identified. Limitations of this study are clear because of the observational concept. Furthermore, the questionnaire we used was not validated. Finally, although the respondents represent a large proportion of Europe, the response rate of 46.3% could have led to response bias.

The basis on which oncological care in a bone sarcoma center is performed differs.

Most bone sarcoma centers are authorized based on expertise, and government authorization has been issued in the countries where the government has extensive responsibilities for national health care. In a considerable number of countries bone tumor guidelines are issued for diagnostic work‐up, referral, and treatment. We believe that these guidelines are a valuable instrument for the clinicians. A recent development is that the European Commission launched an initiative for European Reference Networks (ERN) to create a network of excellence in clinical practice. These networks aim to facilitate discussion on and improve care of complex or rare diseases[10](#os12716-bib-0010){ref-type="ref"}. Furthermore, essential requirements for quality cancer care for soft‐tissue and bone sarcoma in adults were defined by the European CanCer Organization (ECCO)[11](#os12716-bib-0011){ref-type="ref"}. Partially based on these developments, a survey among Italian oncological health care professionals resulted in a set of minimum requirements needed to define a referral center for rare cancers[12](#os12716-bib-0012){ref-type="ref"}.

An interesting finding from our study is the lack of consensus towards authorization of bone sarcoma centers in Germany, as shown in Table [1](#os12716-tbl-0001){ref-type="table"}. Germany is clearly different from the other countries regarding its organization and centralization. Until now, a definition of a bone sarcoma center has never been developed in Germany, resulting in decentralization of bone sarcoma care towards treatment centers.

Decentralization of bone sarcoma care in a country could have adverse effects in terms of delay in diagnosis, misdiagnosis, and inappropriate treatment. Delay in diagnosis in high‐grade bone sarcomas from symptoms until the start of the treatment has been described in the literature[13](#os12716-bib-0013){ref-type="ref"}. Delay is inevitable, but minimizing delay using clear guidelines and referral patterns seems judicious. As mentioned earlier, assessment of radiology and histology by an experienced team is essential for a good prognosis in chondrosarcoma[7](#os12716-bib-0007){ref-type="ref"}. Furthermore, misdiagnosis and subsequent inappropriate treatment resulted in inferior outcomes in osteosarcoma[14](#os12716-bib-0014){ref-type="ref"}. For Ewing sarcoma, inadequate surgical margins are significantly correlated with inferior outcome[15](#os12716-bib-0015){ref-type="ref"}. A study regarding soft‐tissue sarcoma concluded that patients treated in high‐volume hospitals less often had macroscopic residual disease[6](#os12716-bib-0006){ref-type="ref"}.

At an earlier stage, comprehensive incidence estimates were published for all the main primary bone sarcomas in the Netherlands[8](#os12716-bib-0008){ref-type="ref"}. These incidences for high‐grade chondrosarcoma (0.15 per 100,000 European Standardized Rate (ESR)), high‐grade central osteosarcoma (0.25 per 100,000 ESR), and Ewing sarcoma (0.15 per 100,000 ESR) are relatively low compared to other cancer types.

We believe that centralization of care towards a bone sarcoma center is sensible given these incidences, regardless of the basis of authorization or government inference.

In our study, we reproduced the availability of a bone sarcoma center for bone sarcoma patients based on the number of inhabitants of the represented country. A major increase in the adherence per bone sarcoma center could result in a low referral and treatment percentage, with Turkey and Ukraine as an example as shown in Table [1](#os12716-tbl-0001){ref-type="table"}. A possible explanation could be the increased geographical dispersion in the less populated areas of these big countries.

The ECCO expert group recommends that at least 50 bone sarcoma patients are treated in a bone sarcoma center every year[11](#os12716-bib-0011){ref-type="ref"}. This threshold is based on guidance from the British National Institute for Health and Care Excellence (NICE)[16](#os12716-bib-0016){ref-type="ref"}. Conversely, the authors state that this threshold of bone sarcoma in 50 patients every year is dependent on referral patterns and expertise distribution. Bone sarcoma patients are defined by the ECCO as patients with chondrosarcoma, Ewing sarcoma, and osteosarcoma. Furthermore, very rare entities as undifferentiated bone sarcoma, chordoma, and giant cell tumor of bone are defined as bone sarcomas by the ECCO[11](#os12716-bib-0011){ref-type="ref"}. Interestingly, the actual exposure of a bone sarcoma center could be calculated based on our data. A calculation could be made in which the combined incidence for high‐grade chondrosarcoma, high‐grade central osteosarcoma, and Ewing sarcoma (0.55 per 100,000 ESR) is matched with a minimum exposure of 50 bone sarcoma patients for a single bone sarcoma center every year. This is roughly four patients per month. Based on the ECCO recommendation, a single bone sarcoma center should have a minimal adherence of around 9 mn inhabitants to match the exposure of 50 bone sarcoma patients. Based on our study, this exposure can only be matched by bone sarcoma centers in the United Kingdom, Turkey, and Ukraine. However, as mentioned earlier regarding Turkey and Ukraine, more inhabitants per bone sarcoma center could result in a low referral and treatment percentage of bone sarcoma patients, which seems undesirable. Based on our study, the effects of centralization could not be assessed. Therefore, the optimal size for a bone sarcoma center is not known at present. We believe that the participating bone tumors centers in our study provide excellent bone sarcoma care. The recommendation of 50 bone sarcoma patients per year is based on existing evidence as stated in the ECCO article with a reference to the 2006 NICE guidance document[11](#os12716-bib-0011){ref-type="ref"}, [16](#os12716-bib-0016){ref-type="ref"}. In this guidance document, the authors refer to studies from the United Kingdom and Sweden, which conclude that treatment of a bone sarcoma in a specialist center is preferred, without notice of a minimum threshold for treatment per year[17](#os12716-bib-0017){ref-type="ref"}, [18](#os12716-bib-0018){ref-type="ref"}. This suggests that the treatment threshold for a bone sarcoma center of 50 bone sarcoma patients per year is not evidence‐based. We believe that the treatment threshold for a bone sarcoma center per year for adequate treatment of their patients is not known at this moment. To evaluate this, a comparative study between differently sized bone sarcoma centers regarding survival in high‐grade bone sarcoma patients could be a next step. This should give more clarity about the actual effect of centralization of care on survival. Although the treatment threshold is not known, we think that a minimum treatment threshold of at least one bone sarcoma patient every month in a single bone sarcoma center is desirable. This preserves the available expertise of the multidisciplinary team. Reasonably, bone sarcoma centers with little adherence could benefit from a national bone tumor board for extensive case evaluation including classification and advice for treatment from a team with more experience.

A national registry is the basis for adequate monitoring and reporting of outcomes. Furthermore, a complete national registry could provide valuable and comparative big data for collaborative research, which is needed with the given low incidences for high‐grade bone sarcomas. This is emphasized by the previously published collaborative EMSOS studies for several rare entities[19](#os12716-bib-0019){ref-type="ref"}, [20](#os12716-bib-0020){ref-type="ref"}, [21](#os12716-bib-0021){ref-type="ref"}, [22](#os12716-bib-0022){ref-type="ref"}. In our study, the effect of evaluation of care using a national registry was not investigated. Still we think that better evaluation of care, as one can do with a registry, provides essential information to improve quality of care and outcome for bone sarcoma patients.

In conclusion, we believe that centralization of care towards a bone sarcoma center should be mandatory. The optimal size for a bone sarcoma center in terms of patient adherence is not known at this moment. Furthermore, a national registry is essential for the adequate storage and reproduction of oncological data.
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